Most practitioners are trained to treat infections acutely and move on. The deeper clinical problem is what happens when the infection never fully resolves — or when a latent pathogen reactivates months or years later, and the immune system response it triggers begins attacking the patient's own tissue. The Kharrazian Institute teaches practitioners to recognize chronic infections as one of the most underidentified environmental triggers in autoimmune disease development, and the immunological evidence supporting that connection is substantial.
Dr. Datis Kharrazian's clinical training addresses the full sequence of immune dysregulation that connects persistent pathogens to autoimmunity — including the specific mechanisms, the diagnostic patterns that are easy to miss, and the clinical strategies for addressing them in complex chronic patients.
How Chronic Infections Trigger Autoimmune Disease
A patient reports that they were fine until a particular infection. Then, seemingly overnight, their health changed. They never recovered to baseline. Fatigue, pain, cognitive dysfunction, and lab findings consistent with autoimmunity emerged in the months following that infection.
This is not anecdotal. Immunological research demonstrates that persistent infections can corrupt the immune system's ability to distinguish self from non-self — the foundational mechanism behind autoimmune disease. When the immune system remains in a prolonged activation state fighting a chronic pathogen, the threshold for self-tolerance drops. Bystander activation, where immune cells attacking the pathogen also activate against nearby host tissue, becomes more likely the longer the infection persists.
The clinical implication is direct: a patient with an unresolved or latent infection is not just dealing with that pathogen. They may be accumulating the immune conditions that precipitate autoimmunity.
Molecular Mimicry: When the Pathogen Looks Like the Patient
Molecular mimicry is one of the most well-documented mechanisms connecting infections to autoimmune disease. Certain pathogens carry protein sequences — epitopes — that are structurally similar to human tissue proteins. When the immune system generates antibodies against those pathogen epitopes, those same antibodies can cross-react with the patient's own tissues.
Research in autoimmunity has demonstrated molecular mimicry across a range of pathogens and tissue targets. Epstein-Barr virus shares epitopes with myelin proteins in the central nervous system. Certain Borrelia antigens structurally resemble joint tissue. Streptococcal proteins share sequences with cardiac tissue — which is why untreated strep infections can produce rheumatic heart disease.
Dr. Kharrazian's coursework teaches practitioners to think through mimicry patterns systematically. When a patient presents with autoimmune markers and a documented history of a significant infection, molecular mimicry is not a remote possibility — it is a mechanism to investigate actively. The question becomes: which infection, which tissue target, and how long has the cross-reactivity been running.
Viral Reactivation and Its Effect on Immune Regulation
Many of the most clinically relevant infections in chronic autoimmune patients are not new infections. They are reactivations of latent viruses the immune system contained but never eliminated. Epstein-Barr, cytomegalovirus, herpes simplex, and human herpesvirus-6 are the most common in this category.
When immune regulation weakens — from chronic stress, nutritional insufficiency, sleep disruption, or concurrent illness — these latent viruses reactivate. The renewed immune response they provoke is often disproportionate to the actual viral load because the immune system has memory for these pathogens and responds aggressively. That aggressive reactivation response increases inflammatory cytokine output, expands activated T and B cell populations, and creates conditions that are highly permissive for autoimmune tissue damage.
Viral reactivation symptoms rarely present the way an acute infection does. Patients often describe low-grade fatigue, intermittent neurological symptoms, diffuse musculoskeletal pain, or episodes of acute illness that never fully resolve. Because there is no fever spike or obvious acute phase, these presentations are frequently dismissed or misattributed. The research synthesized in Dr. Kharrazian's coursework connects these patterns to measurable immune dysregulation, and teaches practitioners to test for them rather than assume the infection is absent.
Does Chronic Inflammation From Infection Drive Ongoing Autoimmunity?
Persistent infections sustain a state of chronic low-grade inflammation. That sustained inflammatory environment has measurable downstream effects on immune regulation. Regulatory T cell function — the primary brake on autoimmune reactivity — deteriorates under chronic inflammatory conditions. Th1/Th2 balance shifts. Cytokine signaling becomes dysregulated. The immune system loses its capacity to self-correct.
This is not the same as saying infection directly causes autoimmune disease. The more precise clinical model is that infection, combined with genetic susceptibility and other environmental factors, creates an immune environment in which autoimmunity becomes increasingly probable. The infection is the environmental variable that tips the balance.
For patients already diagnosed with an autoimmune condition, an unaddressed chronic or latent infection functions as a perpetuating driver. The autoimmune process does not stabilize because the inflammatory signal sustaining it is still active. These are the patients who fail to respond to standard autoimmune protocols, whose labs remain elevated despite dietary changes and supplementation, and who cycle through flares without a clear trigger. Identifying and addressing the underlying infection often produces clinical improvement when nothing else has.
Which Infections Are Most Clinically Relevant in Autoimmune Patients?
Functional medicine and immunological research have identified several pathogens consistently associated with autoimmune disease development and perpetuation. The clinical relevance of each depends on the patient's tissue targets, autoimmune condition, and immune history.
- Epstein-Barr Virus (EBV): Associated with systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, and rheumatoid arthritis. EBV infects B cells directly and has been shown to interfere with immune tolerance mechanisms. It is the most extensively studied viral trigger in autoimmunity.
- Cytomegalovirus (CMV): Linked to endothelial inflammation and systemic autoimmune patterns. CMV reactivation is particularly relevant in immunocompromised patients and in those with high inflammatory load.
- Borrelia burgdorferi (Lyme disease): Associated with autoimmune arthritis and neurological autoimmunity. Molecular mimicry between Borrelia outer surface proteins and joint tissue proteins is well-documented.
- Human Herpesvirus-6 (HHV-6): Associated with multiple sclerosis and thyroid autoimmunity. HHV-6 can integrate into the human genome, creating a persistent antigenic source even when the virus is not actively replicating.
- Enteroviruses: Research links certain enteroviruses to type 1 diabetes, where molecular mimicry with pancreatic beta cell proteins appears to be a mechanism. Enterovirus infection preceding autoimmune diabetes onset has been demonstrated in prospective studies.
Latent Infection Testing: What Practitioners Are Missing
Standard infectious disease panels are designed to detect acute infections. They are not designed to detect immune reactivity to latent pathogens, reactivation patterns, or low-level persistent infections. A patient can test negative on standard panels while carrying a latent viral burden that is actively driving immune dysregulation.
The more informative clinical approach looks at antibody titers to viral antigens across multiple time points, IgG versus IgM patterns to distinguish past exposure from reactivation, and in some cases, antigen-specific T cell reactivity. Elevated IgG to EBV early antigen, for example, is a marker of reactivation — not simply prior exposure. This distinction matters clinically and is routinely missed when practitioners only order a standard EBV panel.
Dr. Kharrazian's clinical training teaches a systematic thought process for evaluating infection load in autoimmune patients — including which labs to order, how to interpret patterns that suggest reactivation versus latency, and how to sequence therapeutic interventions to support immune regulation without provoking excessive inflammatory responses. For practitioners working with complex autoimmune cases, this sequence of thought is what separates patients who improve from patients who stagnate.
Key Takeaways
- Persistent and latent infections are among the most underidentified environmental triggers in autoimmune disease development, supported by substantial immunological research.
- Molecular mimicry — where pathogen epitopes structurally resemble host tissue proteins — is a documented mechanism through which infections generate cross-reactive autoantibodies.
- Viral reactivation of latent pathogens like EBV, CMV, and HHV-6 can perpetuate immune dysregulation and drive ongoing autoimmune activity even when the original infection appears resolved.
- Standard infectious disease panels frequently fail to detect latent infections or reactivation patterns; more targeted antibody titer analysis and antigen-specific immune testing provide greater clinical utility.
- In autoimmune patients who fail to respond to standard protocols, an unaddressed chronic or reactivated infection is one of the first variables to investigate.
Frequently Asked Questions
Yes. Latent infections can reactivate years after the initial exposure, and molecular mimicry can generate cross-reactive antibodies that persist long after acute illness resolves. Research in autoimmunity demonstrates that the timeline between infection and autoimmune onset is often nonlinear.
Viral reactivation symptoms in autoimmune patients typically include disproportionate fatigue, diffuse musculoskeletal pain, intermittent neurological symptoms, and recurring low-grade illness that does not fully resolve. These presentations rarely include fever or acute phase markers, which is why they are frequently missed clinically.
Molecular mimicry occurs when pathogen protein sequences are structurally similar to host tissue proteins. The immune system generates antibodies against the pathogen, but those antibodies cross-react with host tissue because the antigenic sequences resemble each other. This is a well-documented mechanism in conditions including Hashimoto's thyroiditis, multiple sclerosis, and rheumatic heart disease.
Standard panels detect acute infections, not reactivation patterns. Clinically useful testing for latent infections includes IgG and IgM antibody titers to early and late viral antigens, which distinguish reactivation from prior exposure. In some cases, antigen-specific T cell reactivity testing provides additional diagnostic clarity.
When a chronic or reactivated infection is identified as a perpetuating driver of autoimmune activity, addressing that infection is often necessary for clinical improvement. Patients who fail to stabilize on standard autoimmune protocols frequently show improvement once underlying infection burden and associated immune dysregulation are addressed.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital in the Department of Neurology, specializing in autoimmunity and neuroimmunology. He serves as Associate Clinical Professor at Loma Linda University School of Medicine and is the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn't My Brain Working. Dr. Kharrazian is a Fellow of the American College of Nutrition, Diplomate of the Board of Nutrition Specialists, member of the American Association of Immunologists, and Fellow of the Royal Society of Medicine (UK). The Kharrazian Institute serves more than 5,000 physicians and healthcare providers worldwide.
Clinical Training in Autoimmune Disease
The Kharrazian Institute offers advanced clinical education for practitioners working with autoimmune and chronic inflammatory conditions. Courses cover the mechanisms connecting infections to autoimmunity, evidence-based testing strategies, and personalized protocols for complex patients. Visit the Kharrazian Institute to review current course offerings.
